Dr. Amy Y. Wang, MD
Hematology & Oncology (Hematology & Oncology Physician)
2650 Ridge Ave, Kellogg Cancer Center
Evanston, IL 60201
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 210
Licensed in Illinois since 2018, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Texas Medical School at Houston
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036146158 (first issued 2018; active) -
Internal Medicine Physician
IL license 125065468
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northshore University Healthsystem - Evanston Hospital Evanston, IL
- Swedish Hospital Chicago, IL
Medical groups
- Endeavor Health Medical Group (3,350 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 210
- Services billed
- 698
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 194 | 69 |
| Established patient office or other outpatient visit, 20-29 minutes | 105 | 77 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 59 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 55 | 34 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 42 | 27 |
| New patient office or other outpatient visit, 45-59 minutes | 37 | 37 |
| New patient office or other outpatient visit, 30-44 minutes | 34 | 34 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 23 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Evanston, IL | 101 |
| Revlimid (lenalidomide) | 54 |
| Calquence (acalabrutinib maleate) | 35 |
| Hydroxyurea Other prescribers in Evanston, IL | 29 |
| Eliquis (apixaban) Other prescribers in Evanston, IL | 25 |
| Imatinib Mesylate | 22 |
| Pomalyst (pomalidomide) | 22 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Evanston, IL | 21 |
| Dexamethasone Other prescribers in Evanston, IL | 20 |
| Lenalidomide | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $2,100 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,100 |
|---|
| Consulting Fee | $2,100 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Oct 22, 2025 | Consulting Fee | $2,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $279,880 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First …
Novartis Pharmaceuticals Corporation - A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
Novartis Pharmaceuticals Corporation - Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.